Tag: Glaxo

Posted on

Glaxo in for competition after Hikma’s generic asthma drug passes major milestone – Telegraph.co.uk


Telegraph.co.uk

Glaxo in for competition after Hikma's generic asthma drug passes major milestone
Telegraph.co.uk
Cheap versions of one of GlaxoSmithKline's top-selling asthma drugs could be available to patients as early as next year. Jordanian pharmaceuticals company Hikma moved one step closer to getting a generic version of Glaxo's Advair Diskus inhaler onto …
Cipla's rival Hikma gets asthma drug nod in the USMoneycontrol.com
Vectura and Hikma's generic of Advair Diskus accepted for filing by US FDAThe Pharma Letter (registration)
Vectura Group PLC and Hikma shares given FDA boostProactive Investors UK

all 8 news articles »

View full post on asthma – Google News

Posted on

Independent group says new Glaxo asthma drug far too expensive – Pharmacy Today, American Pharmacists Association, pharmacist.com

Independent group says new Glaxo asthma drug far too expensive
Pharmacy Today, American Pharmacists Association, pharmacist.com
The nonprofit analyzed the once-monthly injectable drug for severe asthma, finding that it should be priced at $7,800 to $12,000 a year, compared with the current list price of $32,500 a year. While the drug significantly reduces asthma attacks and …

View full post on asthma – Google News

Posted on

Glaxo asthma drug clears key hurdle in Europe – MarketWatch


Yahoo News

Glaxo asthma drug clears key hurdle in Europe
MarketWatch
LONDON–GlaxoSmithKline PLC's [GSK.LN] new severe-asthma medicine has received a positive opinion from the scientific committee of the European Medicines Agency for use in adults, clearing a key hurdle towards gaining marketing approval in Europe.
EU regulator backs approval for GSK injectable asthma drugYahoo News
GlaxoSmithKline plc (ADR) To Lead Asthma MarketBidness ETC
GlaxoSmithKline's asthma injection heads for EU approvalFierceBiotech

all 24 news articles »

View full post on asthma – Google News

Posted on

Glaxo Asthma Drug Stumbles in Ambitious Heart Patient Study – Bloomberg


The Express Tribune

Glaxo Asthma Drug Stumbles in Ambitious Heart Patient Study
Bloomberg
GlaxoSmithKline Plc's Breo Ellipta medicine didn't extend lives in an ambitious study that sought to show the drug could help patients suffering from both lung and heart troubles. Patients taking the inhaled asthma drug Breo were 12 percent less likely …
GSK inhaler trial fails to show longer lifeMarketWatch
Respiratory drug trial failure deals blow to GSK revival planFinancial Times
GSK and Theravance Announce Results From the SUMMIT COPD CV Survival StudyCNNMoney
StreetInsider.com –Medical Xpress
all 60 news articles »

View full post on asthma – Google News

Posted on

Glaxo submits new asthma drug application in Japan – MarketWatch

Glaxo submits new asthma drug application in Japan
MarketWatch
LONDON–Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Friday it has submitted a new drug application to the Japanese health ministry for mepolizumab, a drug used for treating a type of severe asthma. The application for mepolizumab has …
Glaxo Submits Japan Application For Mepolizumab In Eosinophilic AsthmaLondon South East

all 2 news articles »

View full post on asthma – Google News

Posted on

FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug – Fox News


Fox News

FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Fox News
The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma …
GlaxoSmithKline And Theravance: The Asthma Approval In FiguresSeeking Alpha
GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma …Bidness ETC
FDA Okays Breo Ellipta for Asthma in AdultsMedscape
Bloomberg
all 81 news articles »

View full post on asthma – Google News

Posted on

US FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug – Reuters


Reuters

US FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters
(Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger …
GlaxoSmithKline plc (ADR) Gets FDA Approval For Breo Ellipta To Treat Asthma …Bidness ETC
FDA Okays Breo Ellipta for Asthma in AdultsMedscape
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
WRAL Tech Wire
all 65 news articles »

View full post on asthma – Google News

Posted on

FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug – Reuters


Reuters

FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters
(Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger …
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the USMarketWatch
FDA Okays Breo Ellipta for Asthma in AdultsMedscape
StreetInsider.com –CNNMoney –HCPLive
all 23 news articles »

View full post on asthma – Google News